All patients included in Follicum's Phase II study with FOL-005 for stimulation of hair growth
Follicum AB today announced that all patients have been included in the company's ongoing Phase IIa clinical study with its lead drug candidate FOL-005. The study involves more than 200 male patients with hair loss who are being treated with a newly developed topical formulation of FOL-005. No noteworthy adverse reactions have been reported so far and to date none of the patients included have discontinued their participation in the study. The results are expected to be presented in spring 2021.The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy